Journal of Clinical Lipidology
Volume 3, Issue 3 , Pages 187-194 , May 2009

Association between the FABP2 Ala54Thr, PPARα Leu162/Val, and PPARα intron7 polymorphisms and blood lipids ApoB and ApoCIII in hypertriglyceridemic subjects in Tehran

  • Hamideh Pishva, PhD

      Affiliations

    • Department of Nutrition and Biochemistry, School of Public Health and Institute of Public Research, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Soltan Ali Mahboob, PhD

      Affiliations

    • Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
    • Corresponding Author InformationCorresponding author.
    • ,
  • Parvin Mehdipour, PhD

      Affiliations

    • Department of Medical Genetic, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Mohammad Reza Eshraghian, PhD

      Affiliations

    • Department of Epidemiology and Biostatistics, School of Public Health and Institute of Public Research, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Javad Mohammadi-Asl, MS

      Affiliations

    • Department of Genetics, School of Medicine, Ahvaz Jondishapur University of Medical Sciences, Ahvaz, Iran
    • ,
  • Saeed Hosseini, MD, PhD

      Affiliations

    • Endocrinology Metabolism Research Center (EMRC), Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Mazaher Rahmany, BS

      Affiliations

    • Endocrinology Metabolism Research Center (EMRC), Tehran University of Medical Sciences, Tehran, Iran

Received 4 September 2008 ,Accepted 13 April 2009.

References 

  1. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96:2520–2525
  2. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886–1892
  3. Alaupovic P. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol. 1996;263:32–60
  4. Georgopoulos A, Aras O, Tsai MY. Codon-54 polymorphism of the fatty acid-binding protein 2 gene is associated with elevation of fasting and postprandial triglyceride in type 2 diabetes. J Clin Endocrinol Metab. 2000;85:3155–3160
  5. Boord JB, Fazio S, Linton MF. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol. 2002;13:141–147
  6. Baier LJ, Sacchettini JC, Knowler WC, et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest. 1995;95:1281–1287
  7. Woratzek PD, Hegele RA, Wolever TM. Postprandial lipemia in subjects with the threonine 54 variant of the fatty acid-binding protein 2 gene is dependent on the type of fat ingested. Am J Clin Nutr. 2004;79:1110–1117
  8. Ito K, Nakatani K, Fujii M, et al. Codon 54 polymorphism of the fatty acid binding protein gene and insulin resistance in the Japanese population. Diabetes Med. 1999;16:119–124
  9. Rissanen J, Pihlajamaki J, Heikkinen S, Kekalainen P, Kuusisto J, Laakso M. The Ala54Thr polymorphism of the fatty acid binding protein 2 gene does not influence insulin sensitivity in Finnish nondiabetic and NIDDM subjects. Diabetes. 1997;46:711–712
  10. Baier LJ, Bogardus C, Sacchettini JC. A polymorphism in the human intestinal fatty acid binding protein alters fatty acid transport across Caco-2 cells. J Biol Chem. 1996;271:10892–10896
  11. Gouni-Berthold I, Giannakidou E, Muller-Wieland D, et al. Association between the PPARalpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. Am Heart J. 2004;147:1117–1124
  12. Tai ES, Corella D, Demissie S, et al. Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr. 2005;135:397–403
  13. Sapone A, Peters JM, Sakai S, et al. The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics. 2000;10:321–333
  14. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32:5598–5604
  15. Lacquemant C, Lepretre F, Pineda Torra I, et al. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab. 2000;26:393–401
  16. Sonnino R, Ereso G, Arcuni J, Franson R. Human intestinal fatty acid binding protein in peritoneal fluid is a marker of intestinal ischemia. Transplant Proc. 2000;32:1280
  17. Flavell DM, Pineda Torra I, et al. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia. 2000;43:673–680
  18. Nielsen EM, Hansen L, Echwald SM, et al. Evidence for an association between the Leu162Val polymorphism of the PPARalpha gene and decreased fasting serum triglyceride levels in glucose tolerant subjects. Pharmacogenetics. 2003;13:417–423
  19. Tai ES, Demissie S, Cupples LA, et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2002;22:805–810
  20. Sparso T, Hussain MS, Andersen G, et al. Relationships between the functional PPARalpha Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people. Mol Genet Metab. 2007;90:205–209
  21. In:  Ordovas JM editors. Fast ultracentrifugation methods for the separation of plasma lipoproteins. Boston MA: Springer-Verlag; 1998;p. 93–110
  22. Vimaleswaran KS, Radha V, Mohan V. Thr54 allele carriers of the Ala54Thr variant of FABP2 gene have associations with metabolic syndrome and hypertriglyceridemia in urban South Indians. Metabolism. 2006;55:1222–1226
  23. Vohl MC, Lepage P, Gaudet D, et al. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res. 2000;41:945–952
  24. Jamshidi Y, Montgomery HE, Hense HW, et al. Peroxisome proliferator-activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation. 2002;105:950–955
  25. Georgopoulos A, Bloomfield H, Collins D, et al. Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT). Atherosclerosis. 2007;194:169–174
  26. Janka HU, Ziegler AG, Standl E, Mehnert H. Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics. Diabetes Metab. 1987;13:359–364
  27. Weiss EP, Brown MD, Shuldiner AR, Hagberg JM. Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effects. Physiol Genomics. 2002;10:145–157
  28. Marin C, Perez-Jimenez F, Gomez P, et al. The Ala54Thr polymorphism of the fatty acid-binding protein 2 gene is associated with a change in insulin sensitivity after a change in the type of dietary fat. Am J Clin Nutr. 2005;82:196–200
  29. Pihlajamaki J, Rissanen J, Heikkinen S, Karjalainen L, Laakso M. Codon 54 polymorphism of the human intestinal fatty acid binding protein 2 gene is associated with dyslipidemias but not with insulin resistance in patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1997;17:1039–1044
  30. Galluzzi JR, Cupples LA, Meigs JB, Wilson PW, Schaefer EJ, Ordovas JM. Association of the Ala54-Thr polymorphism in the intestinal fatty acid-binding protein with 2-h postchallenge insulin levels in the Framingham Offspring Study. Diabetes Care. 2001;24:1161–1166
  31. Duarte NL, Colagiuri S, Palu T, Wang XL, Wilcken DE. Obesity, type II diabetes and the Ala54Thr polymorphism of fatty acid binding protein 2 in the Tongan population. Mol Genet Metab. 2003;79:183–188
  32. Pratley RE, Baier L, Pan DA, et al. Effects of an Ala54Thr polymorphism in the intestinal fatty acid-binding protein on responses to dietary fat in humans. J Lipid Res. 2000;41:2002–2008
  33. Vidgren HM, Sipilainen RH, Heikkinen S, Laakso M, Uusitupa MI. Threonine allele in codon 54 of the fatty acid binding protein 2 gene does not modify the fatty acid composition of serum lipids in obese subjects. Eur J Clin Invest. 1997;27:405–408
  34. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. The effect of polymorphism in the intestinal fatty acid-binding protein 2 gene on fat metabolism is associated with gender and obesity amongst non-diabetic Japanese-Americans. Diabetes Obes Metab. 2004;6:45–49
  35. Lara-Castro C, Hunter GR, Lovejoy JC, Gower BA, Fernandez JR. Association of the intestinal fatty acid-binding protein Ala54Thr polymorphism and abdominal adipose tissue in African-American and Caucasian women. J Clin Endocrinol Metab. 2005;90:1196–1201
  36. Robitaille J, Brouillette C, Houde A, et al. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet. 2004;49:482–489
  37. Sparso T, Hussain MS, Andersen G. Relationships between the functional PPARαLeu162Val polymorphism and obesity, type 2 diabetes, dyslipidemia, and related quantitative traits in studies of 5799 middle-aged white people. Mol Genet Metab. 2007;90:205–209
  38. Evans D, Aberle J, Wendt D, Wolf A, Beisiegel U, Mann WA. A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med. 2001;79:198–204
  39. Uthurralt J, Gordish-Dressman H, Bradbury M, et al. PPARalpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Med Genet. 2007;8:55
  40. Flavell DM, Jamshidi Y, Hawe E, et al. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation. 2002;105:1440–1445
  41. Foucher C, Rattier S, Flavell DM, et al. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics. 2004;14:823–829

PII: S1933-2874(09)00148-2

doi: 10.1016/j.jacl.2009.04.001

Journal of Clinical Lipidology
Volume 3, Issue 3 , Pages 187-194 , May 2009

Article Tools

* Image Usage & Resolution